One candidate of interest is the alpha-2A adrenoceptor agonist, guanfacine, marketed as Tenex (immediate release) and Intuniv (extended release) for treatment of attention-deficit hyperactivity disorder (ADHD). This evidence concerns the gene ADRA2A and attention deficit-hyperactivity disorder.